

## SAN-300

SAN-300, an anti-VLA-1 antibody, AN-300 Indication: Rheumatoid Arthritis & Ulcerative Colitis Response to Disease-Modifying Anti-rheumatic Drug

Company has completed a Phase I clinical program with SAN-300, an investigational monoclonal antibody.

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases. We are focused on constantly innovating to improve patients' lives.

We gain a deeper understanding of the GI conditions our products treat by connecting with the patients who use them and the healthcare professionals (HCPs) who prescribe them. Our therapeutic areas of expertise include management of conditions, such as type 2 diabetes, hepatic encephalopathy, irritable bowel syndrome with diarrhea, opioid-induced constipation, and ulcerative colitis.

We employ dedicated and innovative team members who are driven to problem-solve. We strive to improve upon existing treatments, uncover new breakthroughs, and deliver comprehensive practice support to arm HCPs with life-changing solutions.

The landscape of healthcare will continue to change, and new patients will continue to present with new needs. That's why there is no finish line for our innovation and no limit to our potential.